Ryanodine receptor inhibitors and methods relating thereto

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8703804
APP PUB NO 20070254849A1
SERIAL NO

11728834

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention provides novel ryanodine receptor type 2 (RyR2) inhibitors and methods of their use in the treatment of cardiac conditions. In general, the RyR2 inhibitors of the present invention assist in the normalization of intracellular calcium homeostasis. In certain embodiments, the RyR2 inhibitors are store-overload-induced Ca2+ release (SOICR) inhibitors that minimally inhibit or do not inhibit Ca2+-induced Ca2+ release (CICR), thereby providing beneficial effects in cardiac therapy.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
UTI LIMITED PARTNERSHIP3655 36 STREET NW CALGARY T2L 1Y8

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Back, Thomas G Calgary, CA 6 22
Chen, S R Wayne Calgary, CA 1 1
Jiang, Dawei Brookline, US 9 21
Vembaiyan, Kannan Ottawa, CA 1 6

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Oct 22, 2025
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00